Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
LONDON, Sept. 1, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the appointment of Dr. Nigel McCracken as the Company's Chief Operating Officer ("COO").
- LONDON, Sept. 1, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the appointment of Dr. Nigel McCracken as the Company's Chief Operating Officer ("COO").
- "We are excited to welcome Dr. McCracken to our executive team," commented Mr. James Foster, Chairman of the Board and Chief Executive Officer of Virax.
- Prior to joining Virax, Dr. McCracken was the Chief Scientific Officer at OTC traded BerGenBio AsA where he drove the plan for BerGenBio AsA's companion diagnostics and assay development.
- In addition, Mark Ternouth, Virax's current Chief Technology Officer, will be joining the company's Board of Directors.